Biparametric MRI detects prostate tumors with an accuracy similar to that of multiparametric MRI without the cost and risks associated with intravenous gadolinium contrast.
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Postoperative radiation therapy with adjuvant chemotherapy prolonged disease-free survival and overall survival in patients with locally advanced urothelial carcinoma.
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.